

December 21, 2010



Quick-Med Successfully Completes Joint Development Agreement for NIMBUS(R) Antimicrobial Catheters

Program Marks First Thermoplastics Application for Proprietary NIMBUS(R) Antimicrobial Technology

GAINESVILLE, Florida, Dec. 21, 2010 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCBB:QMDT) announced today that it has successfully completed its joint development program with Foster Corporation, a member of PolyMedex Discovery Group, to collaborate in applying Quick-Med's proprietary NIMBUS® technology to thermoplastics for catheters and other medical product applications.

"Completion of our development work with Foster to incorporate our non-leaching, highly effective NIMBUS antimicrobial technology in catheters represents a key milestone for Quick-Med," said J. Ladd Greeno, CEO of Quick-Med Technologies. "By design, a NIMBUS antimicrobial catheter is far more advanced than any other antimicrobial catheter on the \$14 billion market because the active antimicrobial molecule is integrated into the device and will not migrate into surrounding tissue or engender bacterial resistance."

Catheter-associated urinary tract infection is the most common nosocomial infection. Each year, urinary catheters are inserted in more than 5 million patients in U.S. acute-care hospitals and extended-care facilities. More than 1 million of those patients acquire a catheter-associated urinary tract infection. When infection occurs, the potential medical and economic consequences can be tremendous, including increased mortality and significant additional health care costs.

What makes NIMBUS different from any other antimicrobial technology is its permanent

bond and its ability to be effective even in the presence of large amounts of serum and body fluids, a critical consideration with products inserted into the body. The active agent is permanently bonded to the substrate, keeping the biocide from depletion, while killing microbes (such as MRSA, VRE, and many others) that are present on the device. NIMBUS has an excellent safety record, in comparison to the well-documented toxic effects of silver-based antimicrobials.

About Foster Corporation

For over two decades, Foster Corporation has been a leading supplier of custom polymer compounds for advanced medical devices, blending standard polymers with performance additives or other polymers to achieve properties specific to each device. Foster is part of PolyMedex Discovery Group, a privately held service provider to medical industry offering specialty polymers, custom polymer blends, custom extrusions, and contract material blending for drug delivery. The organization markets and sells to medical and pharmaceutical companies globally. For more information, see: www.polymedexgroup.com.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. Quick-Med commercialized its NIMBUS technology in traditional wound care products in 2009 and is developing NIMBUS applications in several other medical device areas including adhesives, foams, hydrogels, films, hydrocolloids, and catheters. Additionally, its new *Stay Fresh*™ technology provides highly durable antimicrobial protection for apparel and other textile applications and its NimbuDerm™ technology is being developed as a persistent hand sanitizer. For more information, see: www.quickmedtech.com.

The Quick-Med Technologies, Inc. logo is available at <https://www.globenewswire.com/newsroom/prs/?pkgid=8260>

CONTACT: Quick-Med Technologies

J. Ladd Greeno, CEO
(888) 835.2211 Ext 102
lgreeno@quickmedtech.com

The Ruth Group
Media
Eric Reiss
(646) 536-7032
ereiss@theruthgroup.com
Investors
Ashleigh Barreto
(646) 536-7028
abarreto@theruthgroup.com



Source: Quick-Med Technologies, Inc.